Capecitabines

Capecitabine is an oral chemotherapy medication used to treat certain types of cancer. It is classified as a prodrug, meaning it is converted into its active form, 5-fluorouracil (5-FU), within the body. This conversion is thought to occur preferentially in tumor cells, potentially leading to a higher concentration of the active drug at the cancer site and reduced systemic toxicity.

The primary mechanism of action of 5-FU, the active metabolite of capecitabine, involves interfering with DNA and RNA synthesis. By inhibiting thymidylate synthase, an enzyme crucial for DNA production, 5-FU disrupts the replication of rapidly dividing cancer cells. This ultimately leads to cell death.

Capecitabine is commonly prescribed for the treatment of metastatic breast cancer, particularly in patients who have progressed after other chemotherapy regimens. It is also used for metastatic colorectal cancer and advanced gastric cancer. The dosage and duration of treatment are determined by the specific type and stage of cancer, as well as the patient's overall health and response to therapy.

Like all medications, capecitabine can cause side effects. Common adverse reactions include diarrhea, nausea, vomiting, hand-foot syndrome (redness, swelling, and pain on the palms of the hands and soles of the feet), fatigue, and mouth sores. More serious side effects can occur, and patients are advised to report any concerning symptoms to their healthcare provider. Regular monitoring of blood counts and other laboratory values is essential during treatment.